- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04170374
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-South Africa (SPRINT-SA)
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa: The SPRINT Study in South Africa
In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for HIV. The South African National Department of Health adopted this recommendation in October 2017. Neither organization provided detailed guidance, however, on how to implement the recommendation.
In sub-Saharan Africa, where most HIV patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications (ARVs). Among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for HIV is dispensed an initial supply of medications. There is very little published evidence on the practical details of the process and the extent to which it varies by facility, setting, or country. Without a robust baseline evidence base, it is challenging to identify opportunities for making improvements. The SPRINT (Survey of Procedures and Resources for Initiating Treatment of HIV in Africa) study will begin to develop this evidence base. SPRINT will combine a facility-level description of the standard of care with a retrospective record review of patients who recently initiated ART at the study sites. Data will be collected from 12 clinics across 3 provinces in South Africa (KwaZuluNatal Province, Gauteng Province, and Limpopo Province). The survey will elicit detailed information about current procedures through structured interviews with clinic staff. The record review for a retrospective cohort of patients eligible for ART will estimate actual numbers of clinic visits, services provided, and duration of the steps for treatment initiation from start to finish. SPRINT is expected to identify differences in approaches to treatment initiation and potential opportunities for improvement.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2193
- Amy Huber
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥18 years old
- HIV-positive
Exclusion Criteria:
- Pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients who initiated HIV treatment
|
The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
|
Service providers at study facilities
|
Clinicians and lay staff will be interviewed regarding the ART initiation process.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average numbers of visits required to start ART
Time Frame: Up to 6 months after treatment eligibility determined
|
Number of health system interactions required between HIV diagnosis and first dispensing of ARVs
|
Up to 6 months after treatment eligibility determined
|
Time to ART initiation
Time Frame: Up to 6 months after treatment eligibility determined
|
Average number of days required between HIV diagnosis and first dispensing
|
Up to 6 months after treatment eligibility determined
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sydney B Rosen, MPA, BU School of Public Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- H-39330
- OPP1136158 (Other Grant/Funding Number: Bill and Melinda Gates Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
-
National Taiwan UniversityRecruiting
Clinical Trials on Routine medical record data collection
-
Boston UniversityBill and Melinda Gates Foundation; University of Witwatersrand, South Africa; Clinton Health Access Initiative Inc...Active, not recruitingHIV | Antiretroviral TherapySouth Africa, Zambia
-
Boston UniversityBill and Melinda Gates Foundation; University of Witwatersrand, South Africa; Clinton Health Access Initiative Inc...Active, not recruitingHIV | Antiretroviral TherapyMalawi, South Africa
-
Boston UniversityBill and Melinda Gates Foundation; University of Witwatersrand, South AfricaRecruiting
-
Boston UniversityBill and Melinda Gates Foundation; University of Witwatersrand, South Africa; Clinton Health Access Initiative Inc...Recruiting
-
Boston UniversityBill and Melinda Gates Foundation; University of Witwatersrand, South Africa; Clinton Health Access Initiative Inc...Recruiting
-
University Hospital, Basel, SwitzerlandCompletedValgus Malalignment of the KneeSwitzerland
-
University Hospital, Basel, SwitzerlandCompleted
-
Indiana UniversityActive, not recruitingMelanoma; Renal Cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell NeoplasmUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted